Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...
Novo Nordisk A/S (NYSE:NVO) is one of the two major pharmaceutical companies competing in the GLP-1 weight loss market, with ...
Many employers and insurers are scaling back coverage of Wegovy and Zepbound, and a key government program, Medicare, doesn’t ...
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...
A major nonprofit hospital also faced blowback for buying an ad spot during the Super Bowl. NYU Langone ran a 30-second commercial featuring several of its physicians, including Dr. Howard Riina and ...
On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...
Eli Lilly is making a bold move with its experimental weight-loss pill, orforglipron, by recording nearly $550 million in ...
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...
We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we ...
Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...